Navigation Links
Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche
Date:9/9/2008

TORONTO, Sept. 9 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that RiskMetrics ISS Canada, Canada's leading independent proxy firm, has indicated that they have no objection to the transaction, and are recommending that ARIUS shareholders and warrant holders vote FOR the proposed plan of arrangement whereby Roche will acquire all of ARIUS' outstanding shares and warrants.

"The comprehensive review undertaken by RiskMetrics ISS Canada recommends that ARIUS shareholders and warrant holders vote FOR the Arrangement and, in our opinion, provides significant independent validation that the transaction represents the best option for maximizing shareholder value," said Dr. David S. Young, President and Chief Executive Officer of ARIUS.

A special meeting of ARIUS shareholders and warrant holders will be held at 10:30 a.m. Eastern Time on September 16, 2008 at the Suites at 1 King West, Toronto, Ontario, Canada, M5H 1A1. ARIUS shareholders and warrant holders are encouraged to review the Notice of Special Meeting and Information Circular issued by the Company on August 12, 2008. The Information Circular provides, among other things, a detailed discussion of the process that led to the proposed Arrangement and the reasons behind ARIUS Board of Directors' unanimous recommendation that shareholders vote FOR the transaction. Pending the receipt of court and shareholder approval, the transaction is expected to be completed in late September.

ARIUS' Board asks shareholders and warrant holders to vote their proxy FOR the proposed Arrangement today by signing, dating and returning their proxies. The deadline for receiving proxies is September 12, 2008 at 5:00 p.m. Eastern Time. If shareholders have any questions about the information contained in the Information Circular or require assistance in completing their proxy forms, please conta
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Darius Naigamwalla Appointed Senior Vice President and Head of the Brand Management Practice at Campbell Alliance
2. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
3. ARIUS announces second quarter fiscal 2008 financial results
4. ARIUS presents new findings for anti-cancer antibody programs at AACR
5. ARIUS announces first quarter fiscal 2008 financial results
6. ARIUS 2008 Annual and Special Meeting of Shareholders
7. ARIUS recognized for entrepreneurial excellence
8. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
9. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
10. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
11. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)... , , TRANSPORTATION -- Gone hybrid . . . , F...tomobiles are now posted at the www.fueleconomy.g...developed and maintains for the U.S. Department of...cy. Nine of the top 10 vehicles on the best fuel e...a Prius (51 MPG city; 48 highway). "This list prov...
(Date:11/5/2009)... , PARSIPPANY, N.J., Nov. 5 D... has made a manufacturing alliance with Galenix, S...referred commercial scale manufacturing partner fo..., DSM and Galenix will collaborate on business ...g delivery technologies, based on the strength of ...
(Date:11/5/2009)... , Conference Call on Thursday, November 5, 2...nd VANCOUVER Nov. 5 /PRNewswire-FirstCall/ - OncoG...mpany") (NASDAQ: OGXI ) today reported unaudited ...onths ended September 30, 2009 and reviewed the Co...,, The following consolidated results reflect t...
(Date:11/5/2009)... , SUNNYVALE, Calif., Nov. 5 /PRNewswire-Firs... that its executives will be speaking at the follo...o participate via webcast. , , Cre... Thursday, 12 November, 2009 at 10 a.m...Investor Program, London, England, ...
Breaking Biology Technology:November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8Cepheid to Webcast Upcoming Financial Presentations 2
... Encouraging and Durable Anti-Tumor Activity and ... - Results Presented at the 20th EORTC-NCI-AACR Sy... Cancer Therapeutics -, GENEVA and SAN FRANCISCO,...nnounced the presentation of new data from an,ongo...e Company,s novel,androgen receptor antagonist MDV...
... at 20th EORTC-NCI-AACR Symposium -, SOUTH SAN FR...rstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq:...ncology, today announced positive incremental data...atin in combination with,docetaxel and prednisone ...ctory prostate cancer (HRPC). The expanded and upd...
...oup Corporation,("Sosei"; TSE Mothers Index: 4565)...hat Sosei Co., Ltd., its wholly owned Japanese sub...ement with ASKA Pharmaceuticals Co.,Ltd. ("ASKA", ...zation of,the emergency contraceptive pill SOH-075...ontraceptive "morning after pill",which is used to...
Other Biology Technology:Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 4Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 2Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 3Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 4Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 5Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R)) 2
(Date:11/4/2009)...d obesity in the United States is reaching epidemi...ising on daytime and prime time television devoted...bout the role television plays in obesity, a study... Nutrition Education and Behavior examines how fo...contributor to the problem. , Researchers at the...
(Date:11/4/2009)...wswire/ -- Spectros, developer and manufacturer of...ich shed light on life-threatening diseases, annou...on deals for both its T-Stat® VLS Tissue Oxim...tralia, New Zealand, The Netherlands, Belgium, Lu..., Portugal, Poland, Greece, Turkey, and Russia. T...
(Date:11/4/2009)...What,s the cost of saving a teenage life? When it ...m prescription medication abuse, there,s no price ... unaware that the lock-boxes they,ve installed are...omb of prescription drugs. That,s why MEDNET(TM), ...ies, has formed an exclusive partnership with Axiu...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Spectros Signs New International Distribution Deals 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3Nestle 28R 29 Toll House 28R 29 Refrigerated Cookie Dough Recall Update 50188 1Several HealthFitness Clients Earn National Recognition for Employee Health Initiatives 50186 1Several HealthFitness Clients Earn National Recognition for Employee Health Initiatives 50186 2HIV Patients May Have Stiffer Arteries 50183 1
...ith the American Society for Biochemistry and Mole...of Molecular Life Sciences. The 11-volume work wi...2. Society members will have free access to the on...about the ASBMB partnership with Springer to devel...ive Director of the ASBMB. "This is a very exciti...
... Orange are at increased risk of aggressive recurr...study of 1,495 veterans who underwent radical pros...ed that the 206 exposed to Agent Orange had nearly...ring despite the fact that their cancer seemed rel... their cancer came back with a vengeance: the time...
... , KRas is one of the usual suspects in cancer....umors and has been implicated in the regulation of...t is one of the main focuses of attention of inter...lish new information relating to its molecular bio...ns Biomdiques August Pi i Sunyer (IDIBAPS) and the...
Other Biology News:Springer partners with the American Society for Biochemistry and Molecular Biology 2Agent Orange exposure increases veterans' risk of aggressive recurrence of prostate cancer 2Agent Orange exposure increases veterans' risk of aggressive recurrence of prostate cancer 3New data on the breakdown of the KRas protein 2
CQCS kit for first KR 4i from Thermo Scientific
...idrop 384 offers lower consumption of reagents and...applications. The Multidrop 384 is an automated di... microvolume dispensing into 384- and 96-well plat...g flexibility. It can easily switch from 96- to 38...
Wellpro 96 from Thermo Scientific
Angle Rotor with 323 Sealed Buckets, 4 50 ml from Thermo Scientific
Biology Products: